Stock events for enVVeno Medical Corp. (NVNO)
Several significant events have impacted enVVeno Medical Corp.'s stock price in the past six months. The company received an unfavorable FDA appeal decision regarding its Premarket Approval (PMA) application for the VenoValve. enVVeno Medical reported its Q3 2025 financial results, ending the quarter with $31.0 million in cash and investments and a net loss of $4.5 million. The company announced a 1-for-35 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement and later regained compliance with the Nasdaq minimum bid price requirement. NorthStrive Fund II LP publicly called on enVVeno Medical to halt clinical spending plans and convene a special shareholder meeting to vote on strategic alternatives. The stock price experienced a significant decline over the past 52 weeks.
Demand Seasonality affecting enVVeno Medical Corp.’s stock price
Information regarding the demand seasonality specifically for enVVeno Medical Corp.'s products and services is not available. However, a seasonality analysis for the stock price suggests that January has historically offered the highest probability of positive returns, while March may not be an ideal month for investment. This seasonality relates to stock performance rather than product demand.
Overview of enVVeno Medical Corp.’s business
enVVeno Medical Corp. is a late clinical-stage medical device company in Irvine, California, focused on developing bioprosthetic solutions for venous disease. Their primary products under development are the VenoValve, a surgical replacement venous valve for severe deep Chronic Venous Insufficiency (CVI), and enVVe, a non-surgical, transcatheter-based replacement venous valve also aimed at treating deep venous CVI.
NVNO’s Geographic footprint
enVVeno Medical Corp. operates in the United States, focusing on Medical Device development. The company's operations and principal executive offices are based in Irvine, California.
NVNO Corporate Image Assessment
enVVeno Medical Corp.'s brand reputation has likely been significantly affected by the unfavorable FDA decision for VenoValve, the substantial decline in stock price, activist investor scrutiny, and Nasdaq compliance issues.
Ownership
enVVeno Medical Corporation has a concentrated ownership structure, with a high level of insider and institutional investor holdings. Major institutional owners include Perceptive Advisors Llc, Kingdon Capital Management, L.l.c., CM Management, LLC, Vanguard Group Inc, Geode Capital Management, Llc, Gsa Capital Partners Llp, Jpmorgan Chase & Co, and Jane Street Group, Llc. Yury Zhivilo is a significant individual shareholder. Insiders hold a significant majority of the outstanding shares.
